Clinical Trial

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

Study acronym: GALAHOPPER
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-13
notable Trial sites expanded: 1 -> 14 locations 2026-06-13
Trial Details
NCT Number NCT07554495
Lead Sponsor Alfasigma S.p.A.
Conditions Polyarticular Course Juvenile Idiopathic Arthritis
Enrollment 65 participants
Start Date 2026-05-21
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-12